Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
C. Wohlkoenig, K. Leithner, Y. Li, B. Tang, E. Stacher, A. Olschewski, H. Olschewski (Graz, Austria). Adaptation to hypoxia leads to apoptosis resistance to cisplatin in non-small cell lung cancer (NSCLC) cell line. Eur Respir J 2008; 32: Suppl. 52, 2593

Member's Comments

No comment yet.

Related content which might interest you: HIF-1α modulation by topoisomerase inhibitors in A549, a non-small cell lung cancer cell line Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007 Deguelin enhances chemosensitivity of non-small cell lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 336s Year: 2006 ABCG2 is determinant to SN-38 resistance in non-small cell lung cancer Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Source: Annual Congress 2009 - Lung cancer biology Year: 2009 Proliferative activity of non-small cell lung cancer after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 Predictors of response to ZD1839 (IressaÔ) in refractory non-small cell lung cancer Source: Annual Congress 2004 - Management of lung cancer and innovative therapies Year: 2004 IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer Source: Eur Respir J , 49 (4)  1600711; DOI: 10.1183/13993003.00711-2016 Year: 2017 Survivin expression in non-small cell lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 A non-small cell lung cancer modelling by endogenous κ-ras manipulation Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection Year: 2005 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003 Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Expression of RASGRF2 in non-small cell lung cancer and its effect of transfection on biological behavior of human NSCLC lines H1299 Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012 Implementation study: role of docetaxel after a first line cisplatinum based chemotherapy for non-small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 Magnolol can induce apoptosis in non-small cell lung cancer via caspase-independent pathway Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Treatment of  non-small cell lung cancer (NSCLC) - the state of the art and beyond Source: International Congress 2017 – State of the art session: "Lung cancer" Year: 2017